IAN Group, the country’s single largest early-stage investment platform, has invested in Rymo Technologies, a robotic neuro-rehabilitation startup, in its seed funding round of over INR 10 crore, through its evergreen fund, IAN Angel Fund, with participation from other angel investors.

The fresh capital will be used to accelerate product innovation, expand manufacturing capabilities, and strengthen the company’s presence across India while scaling into international markets, including ASEAN and the Middle East.

Also Read: Wipro Opens GIFT City Hub to Provide Services to Global BFSI Clients

Chirag Shah, Co-founder & CEO, Rymo Technologies says, “Our goal is to democratize world-class rehabilitation so that no patient is left behind due to cost or infrastructure barriers. With this financing, we hope to grow internationally, develop our technology, and give more patients and healthcare professionals access to superior robotic rehabilitation”.

Rymo’s approach focuses on bringing robotic and AI-assisted rehabilitation technology to mid-sized hospitals and physiotherapy clinics at an accessible price point, enabling healthcare providers beyond large metropolitan hospitals to offer advanced rehabilitation services.

Also Read: Nvidia to Sell 1 Million Chips to Amazon by End of 2027

Beyond clinical adoption, the company has built a multi-layered technology foundation that combines patented hardware architecture, proprietary algorithms trained on patient data, and modular system design.

At the core of the platform is a multi-joint robotic rehabilitation system being integrated with AI-driven therapy personalization designed to deliver measurable recovery outcomes. These capabilities, along with regulatory progress and international clinical validation studies, including one currently underway in Italy, create a strong platform for global expansion.

Rymo’s price-performance advantage also positions it uniquely in the market. While global robotic rehabilitation systems can cost several times more, Rymo’s solutions are designed to make advanced rehabilitation accessible to Tier 1/2 clinics, mid-sized hospitals, and emerging healthcare markets that have historically been unable to adopt such technology.

Also Read: KKR Plans to Invest $310 Million in India-Centric E- bus Platform

The company has also made progress on regulatory and international expansion fronts. Rymo has received US FDA classification as a Class II medical device and has signed a distribution partnership with Fourier Rehab to expand into ASEAN markets.

The global neuro-rehabilitation devices market, valued at approximately $2.16 billion and growing at around 14 percent annually, presents a significant opportunity, particularly as healthcare systems seek scalable rehabilitation solutions for rising neurological disorders.

Rymo aims to capture this opportunity by building a connected neuro-rehabilitation ecosystem leveraging robotics, internet of things, virtual reality and other advanced technologies.